U.S. FDA evaluating effectiveness of COVID-19 vaccines against Omicron -Breaking
[ad_1]
(Reuters) – The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against the Omicron coronavirus variant and expects to have more information in the next few weeks.
Janet Woodcock, acting commissioner, stated that the agency was currently testing vaccines in order to determine if they are effective against the variant first identified in South Africa.
According to her, if the reviews show that a change to current vaccines is necessary, both the agencies and the companies will collaborate to quickly develop and test the modification.
There are concerns that the new variant could be resistant to vaccinations, prolonging the COVID-19 pandemic of nearly two years.
According to the U.S. Health Regulatory Agency, the vaccines that have been approved are highly effective in preventing COVID-19 from spreading and the serious medical consequences associated with it. They also urge people to be vaccinated.
FDA also is analyzing the impact the variant could have on currently available therapeutics and diagnostics. Omicron’s impact on high volume antigen and PCR tests in the United States is low, according to a preliminary review.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]